Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the
DEPICT
‐2 study): 52‐week results from a randomized controlled trial
2020 ◽
Vol 22
(9)
◽
pp. 1516-1526
◽
2012 ◽
Vol 74
(3)
◽
pp. 319-323
◽
2004 ◽
Vol 21
(11)
◽
pp. 1204-1212
◽
2000 ◽
Vol 17
(11)
◽
pp. 762-770
◽
Keyword(s):
2019 ◽
Vol 21
(8)
◽
pp. 1906-1913
◽
2009 ◽
Vol 11
(s2)
◽
pp. S-5-S-16
◽